TONIX PHARMACEUTICALS HOLDING CORP. Restricted Cash, Current
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Restricted Cash, Current of $31.50 million as of 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Investments, Current › Restricted Cash and Cash Equivalent, Current
us-gaap:RestrictedCashCurrent · last filed 2022-08-08
- 2022-06-30: Restricted Cash, Current $31.50M.
| Period end | Restricted Cash, Current |
|---|---|
| 2022-06-30 | $31.50M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |